Catabasis Pharmaceuticals

Region Nordamerika
ISIN US14875P2065
Sektor Biotechnologie
Website https://www.catabasis.com/

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.

Artikel über Catabasis Pharmaceuticals

Titel Autor Datum
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare
Hai vor ungefähr 9 Monaten